EOM 1352: Fri 7 June 2024, 11:36
Media Pack
News

Current Edition

Volume 17 Issue 1
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Regional News

That key Gilead breast cancer readout? Try 2024, and don’t get your hopes up: analyst

Gilead Sciences just tipped off what sounded like mixed results for Trodelvy, the cornerstone of the Big Biotech’s oncology ambitions. Now, one analyst suggests inves...
9 March 2022 Regional News bladder | breast
Continue Reading →
Regional News

Gilead drops unclear win for key Trodelvy breast cancer trial, poking holes in CEO’s oncology plan

Gilead Sciences has a lot of its oncology ambitions riding on Trodelvy’s success beyond its existing approvals. While investors have been waiting with bated breath fo...
9 March 2022 Regional News breast | cancer
Continue Reading →
Europe

Tecentriq extends streak with win in breast cancer trial

Roche's checkpoint inhibitor Tecentriq helped extend progression-free survival in a Phase 3 study of patients with a hard-to-treat form of metastatic breast cancer...
4 July 2018 Europe | news breast | cancer
Continue Reading →
Europe

Novel magnetic nanoparticles move from lab to first breast cancer clinical trials

Sandia National Laboratories materials chemist Dale Huber has been working on the challenge of making iron-based nanoparticles the exact same size for 15 years. Now, ...
2 May 2018 Europe breast | cancer
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2025, All Rights Reserved – Powered by Teksyte